ABSTRACT
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Despite overlap between genetic risk loci for ALL and hematologic traits, the etiological relevance of dysregulated blood cell homeostasis remains unclear. We investigated this question in a genome-wide association study (GWAS) of ALL (2666 cases, 60,272 controls) and multi-trait GWAS of 9 blood cell indices in the UK Biobank. We identified 3000 blood cell trait-associated (P<5.0×10−8) variants, explaining 4.0% to 23.9% of trait variation, and including 115 loci associated with blood cell ratios (LMR: lymphocyte/monocyte, NLR: neutrophil/lymphocyte, PLR: platelet/lymphocyte). ALL susceptibility was genetically correlated with lymphocyte counts (rg=0.088, p=4.0×10−4) and PLR (rg= −0.072, p=0.0017). In Mendelian randomization analyses, genetically predicted increase in lymphocyte counts was associated with increased ALL risk (Odds ratio (OR)=1.16, p=0.031) and strengthened after accounting for other cell types (OR=1.48, p=8.8×10−4). We observed positive associations with increasing LMR (OR=1.22, p=0.0017) and inverse effects for NLR (OR=0.67, p=3.1×10−4) and PLR (OR=0.80, p=0.002). Our study shows that a genetically induced shift towards higher lymphocyte counts, overall and in relation to monocytes, neutrophils, and platelets, confers an increased susceptibility to childhood ALL.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by research grants from the National Institutes of Health (NIH) National Cancer Institute (NCI): R03CA245998 (AJD and LK), K99CA246076 (LK), R01CA155461 (JLW, XM) and R01CA175737 (JLW, XM). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte) and in accordance with the UK Biobank Ethics and Governance Framework. UK Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. Ethics approval for establishing the UK Biobank resource was obtained from the North West Centre for Research Ethics Committee (11/NW/0382). This study was approved by Institutional Review Boards at the California Health and Human Services Agency, University of Southern California, Yale University, and the University of California San Francisco. The de-identified newborn dried blood spots for the CCRLP (California Biobank Program SIS request # 26) were obtained with a waiver of consent from the Committee for the Protection of Human Subjects of the State of California.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Corrected text labels in Figure 2
Data Availability
This research was conducted with approved access to UK Biobank data under application number 14105 (PI: Witte) and in accordance with the UK Biobank Ethics and Governance Framework. UK Biobank data are publicly available by request from https://www.ukbiobank.ac.uk. Ethics approval for establishing the UK Biobank resource was obtained from the North West Centre for Research Ethics Committee (11/NW/0382).
This study included the analysis of data derived from biospecimens from the California Biobank Program (CCRLP study). Any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens has been determined to violate the statutory scheme of the California Health and Safety Code Sections 124980(j), 124991(b), (g), (h), and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. This study was approved by Institutional Review Boards at the California Health and Human Services Agency, University of Southern California, Yale University, and the University of California San Francisco. The de-identified newborn dried blood spots for the CCRLP (California Biobank Program SIS request # 26) were obtained with a waiver of consent from the Committee for the Protection of Human Subjects of the State of California.
This study makes use of data from the Kaiser Permanente (KP) Research Program on Genes, Environment and Health (RPGEH) Genetic Epidemiology Research on Adult Health and Aging (GERA) cohort, available from dbGaP (Study Accession: phs000788.v1.p2).
This study also makes use of data generated by the Wellcome Trust Case-Control Consortium available by request from the European Genotype Archive: http://www.ebi.ac.uk/ega (Study Accession: EGAD00000000021). Genotype data for COG ALL cases are available for download from dbGaP (Study Accession: phs000638.v1.p1).
